Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CER-001 in Familial Primary Hypoalphalipoproteinemia
NCT02697136Phase 3Terminated
- Sponsor
- ABIONYX Pharma
- Start
- Dec 2015
- Primary completion
- Oct 2018
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles
- Countries
- 7
01
Overview
A Phase 3 trial of CER-001 in Familial Primary Hypoalphalipoproteinemia (FPH), sponsored by ABIONYX Pharma. Started Dec 2015; status: terminated.
02
Drugs
CER-001
03
Conditions
Familial Primary Hypoalphalipoproteinemia (FPH)
Beyond the preview
Go deeper on NCT02697136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02697136.